Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|April 27, 2017
Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacologyBruce J Melancon, Michael R Wood, Meredith J Noetzel, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 21, 2014
Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100Nellie E Byun, Michael Grannan, Michael Bubser, et al.
ACS Chemical Neuroscience|February 5, 2025
Further Optimization of the mGlu1 PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685Carson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Chemical Neuroscience|August 20, 2014
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodentsMichael Bubser, Thomas M Bridges, Ditte Dencker, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of SchizophreniaMichael R Wood, Meredith J Noetzel, Bruce J Melancon, et al.
Bioorganic & Medicinal Chemistry Letters|May 23, 2019
VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidateDarren W Engers, Bruce J Melancon, Allison R Gregro, et al.
Journal of Medicinal Chemistry|December 12, 2024
Discovery of VU6024578/BI02982816: An mGlu1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition ModelsCarson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Chemical Neuroscience|September 17, 2014
Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7Nidhi Jalan-Sakrikar, Julie R Field, Rebecca Klar, et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|May 4, 2019
2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 diseaseJessica Davidson, Elizabeth Molitor, Samantha Moores, et al.
ACS Chemical Neuroscience|February 28, 2012
The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's DiseaseZixiu Xiang, Analisa D Thompson, John T Brogan, et al.
Pageof 5